Kitea Health is redefining brain health with the world’s first implantable sensor that delivers real-time intracranial pressure data. Our technology provides clinicians with remote, actionable insights to improve care for patients with neurological conditions.
Kitea Health is taking the next step in its growth! It's now live on Snowball, an alternative investment platform, giving people the chance to invest in the MedTech industry and catch an investment opportunity at an early stage company. Learn more on the Kitea Health Snowball investment opportunity, the vision, financial projections, technology, and the market need here.
Kitea Health is celebrating the recognition of its CEO and co-founder, Professor Simon Malpas, as a finalist for the Innovator of the Year award, presented by the Kiwibank, New Zealander of the Year Awards. This acknowledgment signifies the impact of Professor Malpas's extensive work and the innovative approach Kitea Health embodies.
The announcment recognition celebrates his decades of groundbreaking research, from the Auckland Bioengineering Institute at the Univerisity of Auckland, other international life science companies, and now Kitea Health. It underscores the impact of his visionary innovation. With only three finalists selected from the nation, this honor highlights the extraordinary significance of his work and Kitea Health's mission.
Kitea Health are thrilled to announce that Kitea has reached another significant milestone in our mission to enhance the lives of individuals with hydrocephalus. Off the back of the FDA Breakthrough Device Designation, we are proud to join the FDA’s exclusive Total Product Life Cycle Advisory (TAP) program.
As one of only 65 devices worldwide selected for this program, we will benefit from expedited interactions with the FDA, akin to a breakthrough designation on steroids! This program also facilitates crucial engagements with payers and patient groups, underscoring the FDA’s commitment to ensuring innovative products are not only approved but also reimbursed promptly.
Following our initial meeting, we are highly encouraged by the agency’s interest in our product and are eager to advance our efforts to align with Centers for Medicare and Medicaid Services (CMS) and insurance companies in the US.
